AI, Machine Learning & Computational Biology

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Published

on

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

​

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version